

# GLOBAL ECONOMICS | SCOTIA FLASH

February 13, 2020

# US CPI Indicates Core PCE Remains Well Below The Fed's Target

- Headline and core CPI were firmer than consensus expected
- Headline CPI picked up on gas prices
- · Core CPI was unchanged; consensus had expected it to soften
- Fed's preferred core PCE gauge likely remains well below target
- Shelter and health insurance continue to dominate the narrow drivers
- Markets ignored the release and stayed focused on the coronavirus

### US CPI, headline/core, m/m % change, SA, January:

Actual: 0.1 / 0.2 Scotia: 0.2 / 0.2 Consensus: 0.2 / 0.2

Prior: 0.2 / 0.1

### US CPI, headline/core, y/y % change, January:

Actual: 2.5 / 2.3 Scotia: 2.5 / 2.3 Consensus: 2.4 / 2.2 Prior: 2.3 / 2.3

Headline (2.5% y/y) and core CPI (2.3% y/y) inflation came in firmer than consensus expected and in line with Scotia's estimates for both. The details continue to suggest that core PCE inflation remains well below the Fed's 2% policy goal. Treasuries and the USD shook off the release with all of the market focus remaining on the coronavirus concerns.

The gap between core CPI and core PCE inflation likely remains wide (chart 1). Core CPI suggests that core PCE is likely to be unchanged at 1.6% y/y and could face marginal downward pressure when we get the figures at month end. The Fed will remain dovishly focused upon undershooting inflation.

On a weighted contribution basis to the year-over-year change in overall prices, CPI inflation continues to be primarily driven by shelter and health insurance (chart 6, next page). Shelter is contributing a weighted 1.1 percentage points to the headline inflation rate of 2.5% y/y and 1.1 points to the 2.3% core CPI inflation rate. It therefore accounts for 44% of total inflation and 48% of core CPI inflation. Going forward, chart 2 continues to demonstrate how this source of inflation should come under renewed downward pressure because we know that the highly correlated driver is the lagged change in repeat sale home prices which has been decelerating.

Gas prices were up by 7.4% y/y in January which was a sharp acceleration from 0.9% y/y the prior month. With a 3.36% weight in CPI, this category added 0.2% to the year-ago headline inflation rate in January versus December and explained the headline CPI acceleration.


Auto prices are turning less and less inflationary within CPI in the US. New vehicle prices were flat (0.1% y/y and 0% m/m). Used vehicle prices had been a

### **CONTACTS**

Derek Holt, VP & Head of Capital Markets Economics 416.863.7707

Scotiabank Economics derek.holt@scotiabank.com


### **Core PCE Inflation Remains Low**



### US Core CPI Could Face Downside Risk



### Waning Used Vehicle Price Inflation



Sources: Scotiabank Economics, BLS, Manheim.




mild source of upward pressure on CPI but this effect has dropped out (chart 3). Used vehicle prices are now down by -2% y/y and -1.2% m/m versus a peak rate of +2.6% y/y in September. This swing since September has knocked 0.1% off of y/y headline CPI in weighted terms.

Health insurance CPI remains the second hottest source of CPI inflation on a weighted basis and is contributing about 0.25 percentage points to total inflation on a yearago basis. This component was up by 20.5% y/y and another 1.7% m/m but the weight is about 1.17% in CPI. Recall that health insurance in CPI has been heading sharply higher but the same has not been true in PCE in raw terms and especially in weighted contribution terms (charts 4, 5). CPI only takes account of direct spending on health insurance by households whereas PCE also includes spending on their behalf by employer and government plans. Nevertheless, we're getting the first tentative

signs of a top in this driver of CPI.

# US Medical Care Insurance Inflation 25 20 US Urban Health Insurance CPI, NSA 15 10 5 US Medical Care & Hospitalization PCE Price Index, SA 10 11 12 13 14 15 16 17 18 19 20

Sources: Scotiabank Economics, US BLS, US Bureau of Economic Analysis.




Sources: Scotiabank Economics, US BLS, US Bureau of Economic Analysis.


Prescription drug prices were up by only 2.5% y/y and down 0.4% m/m

Upward pressure also came from apparel prices (+0.7%), services (+0.4%) and a little firmer OER (+0.3%).

### January Weighted Contributions to Headline CPI



### Monthly Changes in US Headline CPI Categories





## GLOBAL ECONOMICS | SCOTIA FLASH

February 13, 2020

This report has been prepared by Scotiabank Economics as a resource for the clients of Scotiabank. Opinions, estimates and projections contained herein are our own as of the date hereof and are subject to change without notice. The information and opinions contained herein have been compiled or arrived at from sources believed reliable but no representation or warranty, express or implied, is made as to their accuracy or completeness. Neither Scotiabank nor any of its officers, directors, partners, employees or affiliates accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents.

These reports are provided to you for informational purposes only. This report is not, and is not constructed as, an offer to sell or solicitation of any offer to buy any financial instrument, nor shall this report be construed as an opinion as to whether you should enter into any swap or trading strategy involving a swap or any other transaction. The information contained in this report is not intended to be, and does not constitute, a recommendation of a swap or trading strategy involving a swap within the meaning of U.S. Commodity Futures Trading Commission Regulation 23.434 and Appendix A thereto. This material is not intended to be individually tailored to your needs or characteristics and should not be viewed as a "call to action" or suggestion that you enter into a swap or trading strategy involving a swap or any other transaction. Scotiabank may engage in transactions in a manner inconsistent with the views discussed this report and may have positions, or be in the process of acquiring or disposing of positions, referred to in this report.

Scotiabank, its affiliates and any of their respective officers, directors and employees may from time to time take positions in currencies, act as managers, co-managers or underwriters of a public offering or act as principals or agents, deal in, own or act as market makers or advisors, brokers or commercial and/or investment bankers in relation to securities or related derivatives. As a result of these actions, Scotiabank may receive remuneration. All Scotiabank products and services are subject to the terms of applicable agreements and local regulations. Officers, directors and employees of Scotiabank and its affiliates may serve as directors of corporations.

Any securities discussed in this report may not be suitable for all investors. Scotiabank recommends that investors independently evaluate any issuer and security discussed in this report, and consult with any advisors they deem necessary prior to making any investment.

This report and all information, opinions and conclusions contained in it are protected by copyright. This information may not be reproduced without the prior express written consent of Scotiabank.

™ Trademark of The Bank of Nova Scotia. Used under license, where applicable.

Scotiabank, together with "Global Banking and Markets", is a marketing name for the global corporate and investment banking and capital markets businesses of The Bank of Nova Scotia and certain of its affiliates in the countries where they operate, including, Scotiabanc Inc.; Citadel Hill Advisors L.L.C.; The Bank of Nova Scotia Trust Company of New York; Scotiabank Europe plc; Scotiabank (Ireland) Limited; Scotiabank Inverlat S.A., Institución de Banca Múltiple, Scotia Inverlat Casa de Bolsa S.A. de C.V., Scotia Inverlat Derivados S.A. de C.V. – all members of the Scotiabank group and authorized users of the Scotiabank mark. The Bank of Nova Scotia is incorporated in Canada with limited liability and is authorised and regulated by the Office of the Superintendent of Financial Institutions Canada. The Bank of Nova Scotia is authorised by the UK Prudential Regulation Authority and is subject to regulation by the UK Financial Conduct Authority and limited regulation by the UK Prudential Regulation Authority. Details about the extent of The Bank of Nova Scotia's regulation by the UK Prudential Regulation Authority are available from us on request. Scotiabank Europe plc is authorised by the UK Prudential Regulation Authority and the UK Prudential Regulation Authority.

Scotiabank Inverlat, S.A., Scotia Inverlat Casa de Bolsa, S.A. de C.V., and Scotia Derivados, S.A. de C.V., are each authorized and regulated by the Mexican financial authorities.

Not all products and services are offered in all jurisdictions. Services described are available in jurisdictions where permitted by law.